770 related articles for article (PubMed ID: 28584152)
1. Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection.
Lepak AJ; Zhao M; Berkow EL; Lockhart SR; Andes DR
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584152
[No Abstract] [Full Text] [Related]
2.
O'Brien B; Chaturvedi S; Chaturvedi V
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932367
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.
Boonstra JM; van der Elst KC; Veringa A; Jongedijk EM; Brüggemann RJ; Koster RA; Kampinga GA; Kosterink JG; van der Werf TS; Zijlstra JG; Touw DJ; Alffenaar JWC
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971861
[TBL] [Abstract][Full Text] [Related]
4. Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration.
Maseda E; Grau S; Villagran MJ; Hernandez-Gancedo C; Lopez-Tofiño A; Roberts JA; Aguilar L; Luque S; Sevillano D; Gimenez MJ; Gilsanz F
J Antimicrob Chemother; 2014 Jun; 69(6):1624-32. PubMed ID: 24505092
[TBL] [Abstract][Full Text] [Related]
5. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.
Cross SA; Scott LJ
Drugs; 2008; 68(15):2225-55. PubMed ID: 18840009
[TBL] [Abstract][Full Text] [Related]
6. Candida auris and multidrug resistance: Defining the new normal.
Lockhart SR
Fungal Genet Biol; 2019 Oct; 131():103243. PubMed ID: 31228646
[TBL] [Abstract][Full Text] [Related]
7. Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris.
Kordalewska M; Lee A; Park S; Berrio I; Chowdhary A; Zhao Y; Perlin DS
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29632013
[No Abstract] [Full Text] [Related]
8. Assessment of echinocandin regimens by pharmacokinetic/pharmacodynamic analysis against Candida spp. in paediatric patients.
Xu G; Zhu L; Liao S; Ge T; Yang J
Int J Antimicrob Agents; 2015 Dec; 46(6):631-41. PubMed ID: 26602452
[TBL] [Abstract][Full Text] [Related]
9. Candida Surveillance in Surgical Intensive Care Unit (SICU) in a Tertiary Institution.
Liew YX; Teo J; Too IA; Ngan CC; Tan AL; Chlebicki MP; Kwa AL; Lee W
BMC Infect Dis; 2015 Jul; 15():256. PubMed ID: 26137997
[TBL] [Abstract][Full Text] [Related]
10. In vitro pharmacodynamics and in vivo efficacy of fluconazole, amphotericin B and caspofungin in a murine infection by Candida lusitaniae.
Sandoval-Denis M; Pastor FJ; Capilla J; Sutton DA; Fothergill AW; Guarro J
Int J Antimicrob Agents; 2014 Feb; 43(2):161-4. PubMed ID: 24360922
[TBL] [Abstract][Full Text] [Related]
11. Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.
Andes D; Ambrose PG; Hammel JP; Van Wart SA; Iyer V; Reynolds DK; Buell DN; Kovanda LL; Bhavnani SM
Antimicrob Agents Chemother; 2011 May; 55(5):2113-21. PubMed ID: 21300835
[TBL] [Abstract][Full Text] [Related]
12. From bench to bedside: Perspectives on the utility of pharmacokinetics/pharmacodynamics in predicting the efficacy of antifungals in invasive candidiasis.
Pea F
Mycoses; 2020 Aug; 63(8):854-858. PubMed ID: 32472719
[TBL] [Abstract][Full Text] [Related]
13. Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans.
Louie A; Banerjee P; Drusano GL; Shayegani M; Miller MH
Antimicrob Agents Chemother; 1999 Dec; 43(12):2841-7. PubMed ID: 10582869
[TBL] [Abstract][Full Text] [Related]
14.
Zhao M; Lepak AJ; VanScoy B; Bader JC; Marchillo K; Vanhecker J; Ambrose PG; Andes DR
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378706
[TBL] [Abstract][Full Text] [Related]
15. Micafungin: A Review in the Prophylaxis and Treatment of Invasive Candida Infections in Paediatric Patients.
Scott LJ
Paediatr Drugs; 2017 Feb; 19(1):81-90. PubMed ID: 28083856
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization.
Andes DR; Reynolds DK; Van Wart SA; Lepak AJ; Kovanda LL; Bhavnani SM
Antimicrob Agents Chemother; 2013 Nov; 57(11):5714-6. PubMed ID: 23959319
[TBL] [Abstract][Full Text] [Related]
17. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic Evaluation of Rezafungin (CD101) against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model.
Lepak AJ; Zhao M; Andes DR
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30181375
[TBL] [Abstract][Full Text] [Related]
19. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.
Andes DR; Diekema DJ; Pfaller MA; Marchillo K; Bohrmueller J
Antimicrob Agents Chemother; 2008 Oct; 52(10):3497-503. PubMed ID: 18625768
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology of candidemia and antifungal susceptibility in invasive Candida species in the Asia-Pacific region.
Wang H; Xu YC; Hsueh PR
Future Microbiol; 2016 Oct; 11():1461-1477. PubMed ID: 27750452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]